Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
Sign Up to like & getrecommendations! Published in 2018 at "Gastric Cancer"
DOI: 10.1007/s10120-018-00923-7
Abstract: BackgroundPrespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival benefit from trastuzumab emtansine (T-DM1) versus taxane therapy, and to advance understanding of HER2-positive advanced gastric/gastroesophageal junction… read more here.
Keywords: her2 positive; versus taxane; taxane; versus ... See more keywords